Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 9/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12180347 | 0.86 | DRD2 (0.56) | MAOBMAOAKMT2AHRH3 | |
| SCHEMBL1923222 | 0.85 | MAOB (0.64) | MAOBAPPMAOAACHENR4A2 | |
| SCHEMBL11123480 | 0.84 | MAOB (0.59) | MAOBAPPMAOANR4A2HRH3 | |
| SCHEMBL9908788 | 0.80 | MAOB (0.62) | MAOBAPPMAOAACHENR4A2 | |
| SCHEMBL22407066 | 0.79 | MAOB (0.54) | MAOBAPPMAOANR4A2 | |
| SCHEMBL10991891 | 0.79 | MAOB (0.80) | MAOBAPPMAOANR4A2KMT2A | |
| SCHEMBL12998989 | 0.79 | MAOA (0.60) | MAOBMAOAACHENR4A2SLC26A4 | |
| SCHEMBL12330759 | 0.78 | MAOB (0.67) | MAOBAPPMAOANR4A2HRH3 | |
| SCHEMBL257760 | 0.78 | MAOB (0.67) | MAOBAPPMAOANR4A2HRH3 | |
| SCHEMBL12337966 | 0.77 | RAB9A (0.57) | MAOBAPPHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | MAOB 757/4885APP 3115/4885MAOA 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.